TITILOPE FASIPE to Hydroxyurea
This is a "connection" page, showing publications TITILOPE FASIPE has written about Hydroxyurea.
Connection Strength
1.292
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
Score: 0.861
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
Score: 0.218
-
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. Am J Hematol. 2020 09; 95(9):E242-E244.
Score: 0.165
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
Score: 0.047